AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10610644 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/d
Number of subjects: 1609
Study 10610644 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 2.5 mg/d
Number of subjects: 1609
Study 10610644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1609
Study 10610644 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-progestin (open-label)
Number of subjects: 1609
Study 8738773 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium heparin containers
Number of subjects: 25
Study 8738773 — intervention group
Group type: COMPARATOR
Intervention: Sodium edetate containers
Number of subjects: 25
Study 1879192 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg b.i.d. for 7 consecutive days
Number of subjects: 131
Study 1879192 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg b.i.d. for 7 consecutive days
Number of subjects: 131
Study 1879192 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg b.i.d. for 3 consecutive days
Number of subjects: 131
Study 7104133 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 10 ml
Number of subjects: 26
Study 7104133 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% 2-chloroprocaine 10 ml
Number of subjects: 26
Study 7104133 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined extradural groups
Number of subjects: 26
Study 7104133 — intervention group
Group type: COMPARATOR
Intervention: Non-extradural control group
Number of subjects: 26
Study 30778597 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 120
Study 30778597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30778597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 120
Study 30778597 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 120
Study 28359862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg intravenous bolus)
Number of subjects: 79
Study 28359862 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 79
Study 28359862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 79
Study 25268924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep 101 program (experimental condition)
Number of subjects: 0
Study 25268924 — intervention group
Group type: COMPARATOR
Intervention: Sleep monitoring (control condition)
Number of subjects: 0
Study 25052018 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed back-extrapolation method
Number of subjects: 36
Study 25052018 — intervention group
Group type: COMPARATOR
Intervention: Traditional back-extrapolation method
Number of subjects: 36
Study 21940091 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 2% lidocaine with clonidine (15 μg/mL)
Number of subjects: 50
Study 21940091 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with epinephrine (12.5 μg/mL)
Number of subjects: 50
Study 18602820 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone tablets at 144 mg/day
Number of subjects: 12
Study 18602820 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone tablets at 288 mg/day
Number of subjects: 12
Study 18602820 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy foods providing 96 mg isoflavones/day
Number of subjects: 12
Study 17130246 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct superior approach
Number of subjects: 38
Study 17130246 — intervention group
Group type: COMPARATOR
Intervention: Indirect subacromial approach
Number of subjects: 38
Study 16337447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg once daily
Number of subjects: 1015
Study 16337447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg once daily
Number of subjects: 1015
Study 16337447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg once daily
Number of subjects: 1015
Study 16337447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (all doses)
Number of subjects: 1015
Study 16337447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1015
Study 12459865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.4 mg/day)
Number of subjects: 0
Study 12459865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.4 mg/day) + Antioxidant probucol (250 mg/day)
Number of subjects: 0
Study 9594938 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 92
Study 9594938 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 92
Study 7705385 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt intake (20 mmol d‐1) for 3 days
Number of subjects: 14
Study 7705385 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt intake (200 mmol d‐1) for 3 days
Number of subjects: 14
Study 7705385 — intervention group
Group type: COMPARATOR
Intervention: Low salt intake (20 mmol d‐1) for 7 days
Number of subjects: 14
Study 7705385 — intervention group
Group type: COMPARATOR
Intervention: High salt intake (200 mmol d‐1) for 7 days
Number of subjects: 14
Study 1514166 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low dose aspirin (75 mg) and low intensity anticoagulation (INR 1.5)
Number of subjects: 3667
Study 1514166 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity anticoagulation alone (W)
Number of subjects: 3667
Study 1514166 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin alone (A)
Number of subjects: 3667
Study 1514166 — intervention group
Group type: COMPARATOR
Intervention: Double placebo treatment (P)
Number of subjects: 3667
Study 1514166 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low dose aspirin and low intensity anticoagulation (WA)
Number of subjects: 3667
Study 1514166 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity anticoagulation (W)
Number of subjects: 3667
Study 1514166 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin (A)
Number of subjects: 3667
Study 6504946 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (600 mg to 1400 mg)
Number of subjects: 40
Study 6504946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31658028 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of resin-based surface sealants (SSs)
Number of subjects: 30
Study 31658028 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to artificial UV light
Number of subjects: 30
Study 31658028 — intervention group
Group type: COMPARATOR
Intervention: Mechanically finished and polished surfaces
Number of subjects: 30
Study 29554027 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.0-mm scleral lens
Number of subjects: 35
Study 29554027 — intervention group
Group type: EXPERIMENTAL
Intervention: 18.0-mm scleral lens
Number of subjects: 35
Study 29554027 — intervention group
Group type: EXPERIMENTAL
Intervention: 18.2-mm scleral lens
Number of subjects: 35
Study 29554027 — intervention group
Group type: EXPERIMENTAL
Intervention: All lens designs
Number of subjects: 35
Study 27253768 — intervention group
Group type: COMPARATOR
Intervention: 5 hours of time in bed (TIB) for sleep each night
Number of subjects: 56
Study 27253768 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 hours of time in bed (TIB) for sleep each night
Number of subjects: 56
Study 24902475 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting psychiatric disorders (substance abuse, psychosis, bipolar disorder, schizophrenia, depression)
Number of subjects: 2005
Study 24902475 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic conditions (cerebrovascular disease, dementia, traumatic brain injury, brain tumor, metastatic cancer)
Number of subjects: 2005
Study 24902475 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse/dependence
Number of subjects: 2005
Study 24902475 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain tumors
Number of subjects: 2005
Study 22429229 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation
Number of subjects: 41
Study 22429229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 20060192 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (Rg)
Number of subjects: 60
Study 20060192 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (Gm)
Number of subjects: 60
Study 20060192 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide MR (Gli)
Number of subjects: 60
Study 18036981 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard analgesic care plus immersive VR distraction
Number of subjects: 88
Study 18036981 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesic care
Number of subjects: 88
Study 15452689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (acute intravenous administration within 10 days of burn injury and again 1 week later)
Number of subjects: 43
Study 15452689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (acute intravenous administration)
Number of subjects: 43
Study 15452689 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 43
Study 11849315 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen immunotherapy
Number of subjects: 0
Study 11849315 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 9408071 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg b.i.d. (n = 10)
Number of subjects: 25
Study 9408071 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg b.i.d. (n = 10)
Number of subjects: 25
Study 9408071 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d. (n = 5)
Number of subjects: 25
Study 8010581 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative administration of antibiotics
Number of subjects: 6069
Study 8010581 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged perioperative administration of antibiotics into the postoperative period
Number of subjects: 6069
Study 8010581 — intervention group
Group type: COMPARATOR
Intervention: Multiple postoperative administrations of antibiotics
Number of subjects: 6069
Study 3323851 — intervention group
Group type: EXPERIMENTAL
Intervention: Bellergal Retard (BR)
Number of subjects: 0
Study 3323851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28438435 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy (PT)
Number of subjects: 60
Study 28438435 — intervention group
Group type: COMPARATOR
Intervention: Home exercise (HE) program
Number of subjects: 60
Study 27441418 — intervention group
Group type: EXPERIMENTAL
Intervention: Featback (8 weeks, no therapist support)
Number of subjects: 354
Study 27441418 — intervention group
Group type: EXPERIMENTAL
Intervention: Featback with low-intensity therapist support (weekly)
Number of subjects: 354
Study 27441418 — intervention group
Group type: EXPERIMENTAL
Intervention: Featback with high-intensity therapist support (three times a week)
Number of subjects: 354
Study 27441418 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 354
Study 25275268 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and Diet (TRD)
Number of subjects: 20
Study 25275268 — intervention group
Group type: COMPARATOR
Intervention: Training (TR)
Number of subjects: 20
Study 22902987 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg DAS infusion
Number of subjects: 9
Study 22902987 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg DAS infusion
Number of subjects: 9
Study 22902987 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg DAS infusion
Number of subjects: 9
Study 22902987 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of DAS infusion
Number of subjects: 9
Study 20406154 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking to school daily
Number of subjects: 1362
Study 20406154 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time more than two hours a day
Number of subjects: 1362
Study 20406154 — intervention group
Group type: COMPARATOR
Intervention: Being driven to school daily
Number of subjects: 1362
Study 18272560 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic lumbar selective nerve root block
Number of subjects: 47
Study 18272560 — intervention group
Group type: COMPARATOR
Intervention: Control level (adjacent asymptomatic)
Number of subjects: 47
Study 15989936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursuit-rotor task
Number of subjects: 105
Study 15989936 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror tracing task
Number of subjects: 105
Study 15989936 — intervention group
Group type: COMPARATOR
Intervention: Probabilistic classification task
Number of subjects: 105
Study 12681875 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 35 mg once weekly
Number of subjects: 723
Study 12681875 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 5 mg daily
Number of subjects: 723
Study 10872646 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone dosing regimen of 1600 mg/d for 2 days, 1200 mg/d for 5 days, 1000 mg/d for 7 days, 800 mg/d for 7 days, 600 mg/d for 7 days, and 400 mg/d for 62 days followed by a maintenance dose of 343 mg/d (400 mg/d for 6 of 7 days)
Number of subjects: 77
Study 8864323 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluconate, 4 mg kg‐1 i.v. infusion during cisplatin therapy
Number of subjects: 22
Study 8864323 — intervention group
Group type: COMPARATOR
Intervention: Control group (no calcium supplementation)
Number of subjects: 22
Study 1575068 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 75
Study 2415098 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical framycitin/gramicidin (Sofradex)
Number of subjects: 55
Study 2415098 — intervention group
Group type: COMPARATOR
Intervention: Oxytetracycline/hydrocortisone with polymyxin B (Terracortril)
Number of subjects: 55
Study 30618196 — intervention group
Group type: EXPERIMENTAL
Intervention: Artery-preserving varicocelectomy (APV)
Number of subjects: 302
Study 30618196 — intervention group
Group type: COMPARATOR
Intervention: Artery-ligating varicocelectomy (ALV)
Number of subjects: 302
Study 29971784 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand photography protocol for diagnosing hand dermatitis
Number of subjects: 97
Study 29971784 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of 250 cases screened by a nurse
Number of subjects: 97
Study 27940664 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled laninamivir octanoate (20 mg)
Number of subjects: 343
Study 27940664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 25436803 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2181308 (750 mg intravenously, weekly) plus docetaxel (75 mg/m intravenously, day 1)
Number of subjects: 162
Study 25436803 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone (75 mg/m intravenously, every 21 days)
Number of subjects: 162
Study 25436803 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined arms (LY2181308/docetaxel and docetaxel)
Number of subjects: 162
Study 23030357 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-gauge × 4-mm pen needle
Number of subjects: 41
Study 23030357 — intervention group
Group type: COMPARATOR
Intervention: 32-gauge × 6-mm pen needle
Number of subjects: 41
Study 21041432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary portfolio high in monounsaturated fat
Number of subjects: 24
Study 21041432 — intervention group
Group type: COMPARATOR
Intervention: Dietary portfolio low in monounsaturated fat
Number of subjects: 24
Study 18602082 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent positive-pressure breathing (IPPB)
Number of subjects: 14
Study 18602082 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 14
Study 15747590 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal proportional hazards model
Number of subjects: 0
Study 15747590 — intervention group
Group type: EXPERIMENTAL
Intervention: Data example from child vitamin A supplementation trial
Number of subjects: 0
Study 12030960 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg for 7 days)
Number of subjects: 54
Study 12030960 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 54
Study 12030960 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 54
Study 9933263 — intervention group
Group type: EXPERIMENTAL
Intervention: High titers of antibodies to Chlamydia pneumoniae (IgA or IgG)
Number of subjects: 152
Study 9933263 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum titer of antibodies to cytomegalovirus (CMV)
Number of subjects: 152
Study 7763062 — intervention group
Group type: COMPARATOR
Intervention: Inhaled steroids
Number of subjects: 86
Study 2276774 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cimetidine (32 babies)
Number of subjects: 100
Study 2276774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine therapy (43 babies)
Number of subjects: 100
Study 2276774 — intervention group
Group type: COMPARATOR
Intervention: Control group (68 babies for prophylactic study, 34 babies for treatment study)
Number of subjects: 100
Study 361348 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone/alginate antacid combination
Number of subjects: 37
Study 361348 — intervention group
Group type: COMPARATOR
Intervention: Alginate antacid compound used alone
Number of subjects: 37
Study 31359143 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFi treatment
Number of subjects: 1455
Study 31359143 — intervention group
Group type: COMPARATOR
Intervention: No TNFi treatment (Control)
Number of subjects: 1455
Study 30874766 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 2204
Study 30874766 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 2204
Study 28002688 — intervention group
Group type: EXPERIMENTAL
Intervention: ocrelizumab (600 mg)
Number of subjects: 732
Study 28002688 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 732
Study 25846222 — intervention group
Group type: EXPERIMENTAL
Intervention: Murdoch Bowel Protocol(®)
Number of subjects: 331
Study 25846222 — intervention group
Group type: COMPARATOR
Intervention: Routine bowel management (Control)
Number of subjects: 331
Study 21924882 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d EPA + DHA
Number of subjects: 42
Study 19681657 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 g alcohol daily
Number of subjects: 13
Study 19681657 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic beverages
Number of subjects: 13
Study 18458964 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy laser (LEL) treatment as preventive treatment
Number of subjects: 62
Study 18458964 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy laser (LEL) treatment as therapeutic intervention
Number of subjects: 62
Study 18458964 — intervention group
Group type: COMPARATOR
Intervention: Sham illumination (control)
Number of subjects: 62
Study 15830635 — intervention group
Group type: EXPERIMENTAL
Intervention: Silk sutures (4-0)
Number of subjects: 12
Study 15830635 — intervention group
Group type: COMPARATOR
Intervention: ePTFE sutures (CV-5)
Number of subjects: 12
Study 15830635 — intervention group
Group type: EXPERIMENTAL
Intervention: Both suture materials
Number of subjects: 12
Study 15072038 — intervention group
Group type: EXPERIMENTAL
Intervention: ST‐TENS (75 Hz)
Number of subjects: 33
Study 15072038 — intervention group
Group type: EXPERIMENTAL
Intervention: AL‐TENS (4 Hz)
Number of subjects: 33
Study 15072038 — intervention group
Group type: COMPARATOR
Intervention: ST‐TENS and AL‐TENS
Number of subjects: 33
Study 15072038 — intervention group
Group type: EXPERIMENTAL
Intervention: AL‐TENS
Number of subjects: 33
Study 11085323 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA treatment
Number of subjects: 0
Study 8905358 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration lumpectomy
Number of subjects: 77
Study 8905358 — intervention group
Group type: COMPARATOR
Intervention: Strip biopsy
Number of subjects: 77
Study 1846451 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled uterine incision using the Stapler
Number of subjects: 0
Study 1846451 — intervention group
Group type: COMPARATOR
Intervention: Routine uterine incision (control group)
Number of subjects: 0
Study 6353434 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg prazepam per day
Number of subjects: 2009
Study 6353434 — intervention group
Group type: COMPARATOR
Intervention: 15 mg diazepam per day
Number of subjects: 2009
Study 6353434 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg prazepam (divided dosage)
Number of subjects: 2009
Study 6353434 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg prazepam (single night time dosage)
Number of subjects: 2009
Study 6353434 — intervention group
Group type: COMPARATOR
Intervention: 15 mg diazepam (divided dosage)
Number of subjects: 2009
Study 29779262 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary exRNA biomarkers (SPRR1A, lnc-TET3-2:1, FAM25A, CRCT1)
Number of subjects: 30
Study 29779262 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary exRNA biomarkers
Number of subjects: 30
Study 27198057 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-counseling intervention with a Navigator for up to 6 months
Number of subjects: 104
Study 27198057 — intervention group
Group type: COMPARATOR
Intervention: No further intervention (Control group)
Number of subjects: 104
Study 24714489 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 720
Study 24714489 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) infusion
Number of subjects: 720
Study 24714489 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC in combination with NaHCO3
Number of subjects: 720
Study 24714489 — intervention group
Group type: COMPARATOR
Intervention: Hydration with sodium chloride infusion alone
Number of subjects: 720
Study 24714489 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined NAC and NaHCO3
Number of subjects: 720
Study 24714489 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC
Number of subjects: 720
Study 24714489 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3
Number of subjects: 720
Study 24714489 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride infusion alone
Number of subjects: 720